Clinical Applications of Simultaneous PET/MR Imaging Using (R)-[¹¹C]-Verapamil with Cyclosporin A: Preliminary Results on a Surrogate Marker of Drug-Resistant Epilepsy

REFERENCES

1. 1.↵
   2. Browne TR,
   3. Holmes GL

   . Epilepsy. N Engl J Med 2001;344:1145–51 doi:10.1056/NEJM200104123441507 pmid:11297707

   CrossRefPubMedWeb of Science
2. 2.↵
   2. Löscher W,
   3. Schmidt D

   . Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia 2011;52:657–78 doi:10.1111/j.1528-1167.2011.03024.x pmid:21426333

   CrossRefPubMedWeb of Science
3. 3.↵
   2. Sillanpää M,
   3. Schmidt D

   . Natural history of treated childhood-onset epilepsy: prospective, long-term population-based study. Brain 2006;129:617–24 doi:10.1093/brain/awh726 pmid:16401617

   Abstract/FREE Full Text
4. 4.↵
   2. Löscher W,
   3. Klitgaard H,
   4. Twyman RE, et al

   . New avenues for anti-epileptic drug discovery and development. Nat Rev Drug Discov 2013;12:757–76 doi:10.1038/nrd4126 pmid:24052047

   CrossRefPubMed
5. 5.↵
   2. Löscher W,
   3. Potschka H

   . Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 2005;6:591–602 doi:10.1038/nrn1728 pmid:16025095

   CrossRefPubMedWeb of Science
6. 6.↵
   2. Potschka H

   . Role of CNS efflux drug transporters in antiepileptic drug delivery: overcoming CNS efflux drug transport. Adv Drug Deliv Rev 2012;64:943–52 doi:10.1016/j.addr.2011.12.007 pmid:22210135

   CrossRefPubMed
7. 7.↵
   2. Liu JY,
   3. Thom M,
   4. Catarino CB, et al

   . Neuropathology of the blood-brain barrier and pharmaco-resistance in human epilepsy. Brain 2012;135:3115–33 doi:10.1093/brain/aws147 pmid:22750659

   Abstract/FREE Full Text
8. 8.↵
   2. Muzi M,
   3. Mankoff DA,
   4. Link JM, et al

   . Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: studies of healthy humans. J Nucl Med 2009;50:1267–75 doi:10.2967/jnumed.108.059162 pmid:19617341

   Abstract/FREE Full Text
9. 9.↵
   2. Wagner CC,
   3. Bauer M,
   4. Karch R, et al

   . A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET. J Nucl Med 2009;50:1954–61 doi:10.2967/jnumed.109.063289 pmid:19910428

   Abstract/FREE Full Text
10. 10.↵
    2. Bauer M,
    3. Karch R,
    4. Neumann F, et al

    . Assessment of regional differences in tariquidar-induced P-glycoprotein modulation at the human blood-brain barrier. Cereb Blood Flow Metab 2010;30:510–15 doi:10.1038/jcbfm.2009.265 pmid:20010957

    Abstract/FREE Full Text
11. 11.↵
    2. Dukart J,
    3. Mueller K,
    4. Horstmann A, et al

    . Differential effects of global and cerebellar normalization on detection and differentiation of dementia in FDG-PET studies. Neuroimage 2010;49:1490–95 doi:10.1016/j.neuroimage.2009.09.017 pmid:19770055

    CrossRefPubMedWeb of Science
12. 12.↵
    2. Kwan P,
    3. Arzimanoglou A,
    4. Berg AT, et al

    . Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010;51:1069–77 doi:10.1111/j.1528-1167.2009.02397.x pmid:19889013

    CrossRefPubMedWeb of Science
13. 13.↵
    2. Kang KW,
    3. Lee DS,
    4. Cho JH, et al

    . Quantification of F-18 FDG PET images in temporal lobe epilepsy patients using probabilistic brain atlas. Neuroimage 2001;14:1–6 doi:10.1006/nimg.2001.0783 pmid:11525319

    CrossRefPubMed
14. 14.↵
    2. Lee JS,
    3. Lee DS

    . Analysis of functional brain images using population-based probabilistic atlas. Current Medical Imaging Reviews 2005;1:81–87 doi:10.2174/1573405052953056

    CrossRef
15. 15.↵
    2. Kim DW,
    3. Lee SK,
    4. Chu K, et al

    . Lack of association between ABCB1, ABCG2, and ABCC2 genetic polymorphisms and multidrug resistance in partial epilepsy. Epilepsy Res 2009;84:86–90 doi:10.1016/j.eplepsyres.2008.12.001 pmid:19167193

    CrossRefPubMed
16. 16.↵
    2. Langer O,
    3. Bauer M,
    4. Hammers A, et al

    . Pharmacoresistance in epilepsy: a pilot PET study with the P-glycoprotein substrate R-[(11)C]verapamil. Epilepsia 2007;48:1774–84 doi:10.1111/j.1528-1167.2007.01116.x pmid:17484754

    CrossRefPubMedWeb of Science
17. 17.↵
    2. Feldmann M,
    3. Asselin MC,
    4. Liu J, et al

    . P-glycoprotein expression and function in patients with temporal lobe epilepsy: a case-control study. Lancet Neurol 2013;12:777–85 doi:10.1016/S1474-4422(13)70109-1 pmid:23786896

    CrossRefPubMed
18. 18.↵
    2. Kalvass JC,
    3. Polli JW,
    4. Bourdet DL, et al

    ; International Transporter Consortium. Why clinical modulation of efflux transport at the human blood-brain barrier is unlikely: the ITC evidence-based position. Clin Pharmacol Ther 2013;94:80–94 doi:10.1038/clpt.2013.34 pmid:23588303

    CrossRefPubMed
19. 19.↵
    2. Syvänen S,
    3. Eriksson J

    . Advances in PET imaging of P-glycoprotein function at the blood-brain barrier. ACS Chem Neurosci 2013;4:225–37 doi:10.1021/cn3001729 pmid:23421673

    CrossRefPubMed
20. 20.↵
    2. Taubert D,
    3. von Beckerath N,
    4. Grimberg G, et al

    . Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 2006;80:486–501 doi:10.1016/j.clpt.2006.07.007 pmid:17112805

    CrossRefPubMedWeb of Science
21. 21.↵
    2. Syvänen S,
    3. Blomquist G,
    4. Sprycha M, et al

    . Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood-brain barrier can be studied with PET. Neuroimage 2006;32:1134–41 doi:10.1016/j.neuroimage.2006.05.047 pmid:16857389

    CrossRefPubMed
22. 22.↵
    2. Syvänen S,
    3. Hooker A,
    4. Rahman O, et al

    . Pharmacokinetics of P-glycoprotein inhibition in the rat blood-brain barrier. J Pharm Sci 2008;97:5386–400 doi:10.1002/jps.21359 pmid:18384156

    CrossRefPubMed
23. 23.↵
    2. Deo AK,
    3. Borson S,
    4. Link JM, et al

    . Activity of P-glycoprotein, a β-amyloid transporter at the blood-brain barrier, is compromised in patients with mild Alzheimer disease. J Nucl Med 2014;55:1106–11 doi:10.2967/jnumed.113.130161 pmid:24842892

    Abstract/FREE Full Text
24. 24.↵
    2. Asadi-Pooya AA,
    3. Razavizadegan SM,
    4. Abdi-Ardekani A, et al

    . Adjunctive use of verapamil in patients with refractory temporal lobe epilepsy: a pilot study. Epilepsy Behav 2013;29:150–54 doi:10.1016/j.yebeh.2013.07.006 pmid:23973639

    CrossRefPubMed